Biogen | BIIB - Loan Capital


Biogen reported $7.29B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 1.48B 7.23M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Bayer EUR 30.68B 1.15B Mar/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Incyte USD 28.42M 994K Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Moderna USD 597M 6M Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 14.65B 806M Jun/2026
Sanofi EUR 12.3B 3.42B Mar/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Teva Pharmaceutical Industries USD 12.09B 1.92B Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025